These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 18372138)

  • 1. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis--implications for nephrologists.
    Saab G; Abu-Alfa A
    Eur J Radiol; 2008 May; 66(2):208-12. PubMed ID: 18342470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic system fibrosis: a radiologist's practical perspective.
    Martin DR
    Eur J Radiol; 2008 May; 66(2):220-4. PubMed ID: 18321672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis: clinical spectrum of disease.
    Mayr M; Burkhalter F; Bongartz G
    J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
    Heinrich M; Uder M
    Rofo; 2007 Jun; 179(6):613-7. PubMed ID: 17497597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS; Sheller A
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.
    Abraham JL; Thakral C
    Eur J Radiol; 2008 May; 66(2):200-7. PubMed ID: 18374532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.
    Grant D; Johnsen H; Juelsrud A; Løvhaug D
    Acta Radiol; 2009 Mar; 50(2):156-69. PubMed ID: 19160079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
    Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
    Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M; Thuillier D; Lok C; Gras-Champel V
    Therapie; 2007; 62(2):169-72. PubMed ID: 17582319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular gadolinium contrast agents: differences in stability.
    Morcos SK
    Eur J Radiol; 2008 May; 66(2):175-9. PubMed ID: 18343072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):153-9. PubMed ID: 18343071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J; Snow T; Hiremagalur B
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.